A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.

Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...

Without an easy way to screen and with nondescript symptoms, ovarian cancer is often caught in late stages, requiring massive ...

B ERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall ...

The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no ...

Emily Pwee, 54, developed a fever and cough on Oct. 10, her husband, 54-year-old Jimmy Teo, told Shin Min Daily News . Teo, a ...

Results from the phase 2 (dose optimization) part of the REJOICE-Ovarian01 phase 2/3 trial showed that raludotatug deruxtecan (R-DXd) demonstrated clinically meaningful response rates in patients with ...

Light Chain Bioscience, a clinical-stage biotechnology company advancing the next generation of bispecific antibodies to treat cancer, today presented positive results from a Phase 1/1b study of NI-18 ...

Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer ...

New KEYNOTE-B96 data add to previous results showing progression-free survival (PFS) and overall survival (OS) improvements ...

Families, hospital employees, cancer patients, and survivors gathered on Sunday for the 10th annual Dominique Dagenais Cedars Run for Ovarian Cancer in TMR. The event raised funds for the DOvEEgene ...

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 ...